ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 67 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $707,525 | -63.9% | 172,989 | +39.2% | 0.00% | – |
| Q1 2024 | $1,958,763 | +181.0% | 124,287 | +170.1% | 0.00% | – |
| Q4 2023 | $697,036 | -11.5% | 46,009 | +17.1% | 0.00% | – |
| Q3 2023 | $787,897 | +14.4% | 39,277 | +60.8% | 0.00% | – |
| Q2 2023 | $688,888 | +100.0% | 24,420 | +22.0% | 0.00% | – |
| Q1 2023 | $344,378 | +67.0% | 20,022 | +95.5% | 0.00% | – |
| Q4 2022 | $206,213 | -77.6% | 10,239 | -75.9% | 0.00% | – |
| Q3 2022 | $919,000 | +245.5% | 42,406 | +347.8% | 0.00% | – |
| Q2 2022 | $266,000 | -64.0% | 9,470 | -40.8% | 0.00% | – |
| Q1 2022 | $738,000 | -26.2% | 16,000 | +34.6% | 0.00% | – |
| Q4 2021 | $1,000,000 | -43.1% | 11,889 | -64.0% | 0.00% | -100.0% |
| Q2 2021 | $1,756,000 | +79.2% | 33,000 | +74.8% | 0.00% | – |
| Q4 2020 | $980,000 | +57.1% | 18,876 | +45.3% | 0.00% | – |
| Q2 2020 | $624,000 | – | 12,994 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Mayo Clinic | 187,143 | $765,415 | 25.27% |
| Decheng Capital LLC | 3,070,442 | $12,558,107 | 3.85% |
| MPM BioImpact LLC | 1,450,000 | $5,930,500 | 0.92% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 961,486 | $3,932,478 | 0.80% |
| Eventide Asset Management | 8,547,896 | $34,960,895 | 0.60% |
| 5AM Venture Management, LLC | 490,000 | $2,004,100 | 0.45% |
| Matrix Capital Management Company, LP | 13,959,973 | $57,096,290 | 0.44% |
| Values First Advisors, Inc. | 74,925 | $306,443 | 0.18% |
| Boxer Capital, LLC | 450,000 | $1,840,500 | 0.10% |
| GSA CAPITAL PARTNERS LLP | 255,201 | $1,044 | 0.07% |